Zai Lab Limited, commonly referred to as Zai Lab, is a prominent biopharmaceutical company headquartered in China. Founded in 2014, the company has rapidly established itself as a leader in the development of innovative therapies, focusing primarily on oncology, autoimmune diseases, and infectious diseases. With a strong operational presence in both China and the United States, Zai Lab is committed to addressing unmet medical needs through its robust pipeline of novel drug candidates. The company’s core offerings include a range of proprietary and partnered products, distinguished by their unique mechanisms of action and potential to improve patient outcomes. Zai Lab has achieved significant milestones, including successful collaborations with global pharmaceutical leaders and the launch of several key therapies in the Chinese market. Recognised for its commitment to innovation, Zai Lab continues to strengthen its position in the competitive biopharmaceutical landscape.
How does Zai Lab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zai Lab's score of 17 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Zai Lab reported total carbon emissions of approximately 70,321,000 kg CO2e, comprising 65,642,000 kg CO2e from Scope 1, 4,664,000 kg CO2e from Scope 2, and 70,321,000 kg CO2e from Scope 3 emissions. This represents a significant increase in emissions compared to 2022, where total emissions were about 73,481,000 kg CO2e, with Scope 1 emissions at 70,463,000 kg CO2e and Scope 2 at 3,954,000 kg CO2e. Zai Lab has committed to near-term carbon reduction targets, although specific numerical targets have not been disclosed. The company is not currently committed to a net-zero target. Their emissions data reflects their operations in the pharmaceuticals, biotechnology, and life sciences sector, highlighting the importance of addressing carbon emissions in this industry. Overall, Zai Lab's emissions profile indicates a need for enhanced strategies to manage and reduce their carbon footprint effectively.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2021 | 2022 | 2023 | |
---|---|---|---|
Scope 1 | 28,400 | 00,000,000 | 00,000,000 |
Scope 2 | 3,536,600 | 0,000,000 | 0,000,000 |
Scope 3 | - | 00,000,000 | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zai Lab is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.